This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Endologix's CEO Presents At Morgan Stanley Healthcare Conference (Transcript)

Endologix Inc. (ELX)

Morgan Stanley Healthcare Conference

September 10, 2012 11:45 am ET

Executives

John McDermott - Chairman of the Board, President, Chief Executive Officer

Analysts

Presentation

Unidentified Analyst

Great, let's go ahead and get started here. I look managed care with medical devices. So it’s a pleasure to have with us here the session before we get into the lunch break here, Endologix's CEO, John McDermott. Just quickly for medical device recent disclosures, go to the Morgan Stanley website and you can see all of my recent disclosures. It’s a great read.

So, for many of you know this, that Endologix is not a covered company for Morgan Stanley. So the real question is, why are they here and the route is, we see Endologix is attacking a very large and growing end-market in AAA stenting and John will sort of walk us through that.

I also would say this, since John has joined the company, several years ago, you have seen significant improvement in both their international distribution, their product reps have expanded the business in terms of the pipeline with their acquisition of Nellix. So this business in the last three to four years has been completely transformed and John obviously has a lot to with that.

So we see here is an emerging medical device company in an important growing end market and frankly with a significant amount of operational change. So what we are going to do is let John and he will give us a minute preamble and then we are going to jump into the Q&A. John.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs